Publications by Epividian Scientists and Collaborators


Book Chapters

Fusco GP. Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Healthcare Data—Implications for Clinical Management and Clinical Trial Design: A Case Study of Anemia of Chronic Kidney Disease. In: Rahbari R, Van Niewaal J, Bleavins MR, editors. Biomarkers in Drug Discovery and Development: A Handbook of Practice, Application, and Strategy. 2nd ed. John Wiley & Sons, Inc. ISBN: 978-1-119-18750-9, April 2020.


Pierone G, Henegar C, Fusco J, Vannappagari V, Aboud M, Ragone L, Fusco G.Two-drug antiretroviral regiments: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA Observational Database. J. Int. AIDS Soc. 2019, 22:e25418. DOI: 10.1002/jia2.25418.

Mills A, Brunet L, Fusco JS, Wohlfeiler M, Garris C, Oglesby A, Mrus J, Lackey PC, Fusco GP.Virologic failure among ART-naïve patients initiating dolutegravir, elvitegravir, raltegravir or darunavir. Inf. Dis. Therapy, DOI: 10.1007/s40121-019-00274-5.

Fusco J, Henegar C, Quinlivan EB, Vannappagari V, Aboud M, Smith K, Fusco G.. Integrase inhibitor-based antiretroviral therapy among HIV-1 infected treatment-naïve and treatment-experienced women: data from the OPERA cohort. Current HIV Research (2019) 17: 1.

Heglar R, Mood R, Priest JL, Schulman KL, Fusco GP. Benchmarking HIV Quality Measures in the US OPERA HIV Cohort. Open Forum Infectious Diseases, Volume 6, Issue 10, October 2019, ofz418,

Hsu R, Fusco J, Henegar C, Mounzer K, Wohlfeiler M, Vannappagari V, Aboud M, Curtis L, Fusco G. Psychiatric Conditions Observed in HIV-Infected Patients Using Six Common Core Agents in the OPERA Database. Ther. Adv. Drug Saf. DOI: 10.1177/2042098618798350.

Mounzer K, Hsu R, Fusco J, Brunet L, Henegar C, Vannappagari V, Stainsby C, Shaefer M, Ragone L, Fusco G. HLA-B*5701 Screening and Hypersensitivity Reaction to Abacavir between 1999 and 2016 in the OPERA® Observational Database. In Press. AIDS Research and Therapy.

Fusco G, Hariri A, Vallarino C, Singh A, Yu P, Wise L.  A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of Chronic Kidney Disease.  Ther. Adv. Drug Saf. 2017;8(10):305–318. DOI:10.1177/2042098617716819.

Wohlfeiler M, Carpio F, Lackey P, Henegar C, Fusco J, Jonsson-Funk M, Vonesh E, Fusco G, Melikian G, Hsu R, Pierone G, Dieterich D, Mills A. An evaluation of the impact of integrase strand transfer inhibitor (INSTI) within-class switching on continued viral suppression in the OPERA Cohort. Submitted to Pharmacoepidemiol. Drug Saf.

Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L. Psychiatric symptoms in patients receiving dolutegravir. J. Acquir. Immune Defic. Syndr. 2017;74(4):423-431.

Lackey P, Mills A, Carpio F, Hsu R, DeJesus E, Pierone G, Henegar C, Fusco J, Fusco G, Wohlfeiler M. Virologic effectiveness of abacavir/lamivudine with darunavir versus other protease inhibitors in treatment-experienced HIV-infected patients in clinical practice. Clin. Drug Investig. 2017;37(1):51–60. Download PDF >

Braithwaite RS, Justice AC, Chang CH, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of individuals infected with Human Immunodeficiency Virus who will die of comorbid diseases. Am. J. Med. 2005;118:09.

Raffanti SR, Fusco JS, Sherrill BH, Hansen NI, Justice AC, Mangialardi WJ, D’Aquila R, Fusco GP. Effect of persistent moderate viremia on disease progression during HIV therapy. J. Acquir. Immune Defic. Syndr. 2004;37:1147-1154.

Becker SL, Feinberg J, Fusco JS, Balu RB, Gangjee S, Brennan C, Fusco GP. HIV-associated thrombotic microangiopathy in the post-HAART era: an observational study. Clin. Infect. Dis. 2004;39:S267-75. Download PDF >

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration. Predictors of trend in CD4-positive mortality among HIV-1-infected individuals with virologic failure to all three antiretroviral drug classes. Lancet 2004;364:51-62.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC et al. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. J. Clin. Epidemiol. 2004;57(1):89-97. Download PDF >

King JT, Jr., Justice AC, Roberts MS, Chang CC, Fusco JS. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Making 2003;23(1):9-20.

Becker SL, Raffanti SR, Hansen NI, Fusco JS, Fusco GP, Slatko GH, Igboko E, Graham N. Zidovudine and stavudine sequencing in HIV treatment planning. J. Acquir. Immune Defic. Syndr. 2001;26(1):72-81.